Sign in or Register   Sign in or Register
  |  

Mouse Anti-BCL9 Recombinant Antibody (CBYY-1990) (CBMAB-2339-YY)

This product is mouse antibody that recognizes BCL9. The antibody CBYY-1990 can be used for immunoassay techniques such as: ELISA, IF, WB
See all BCL9 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-1990
Antibody Isotype
IgG2b
Application
WB

Basic Information

Immunogen
E. coli-derived recombinant human Bcl-9 Met1009-Gly1328.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2b
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB0.5 μg/ml

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Lyophilized
Buffer
PBS, Trehalose
Preservative
None
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
B-cell CLL/lymphoma 9
Introduction
BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.
Entrez Gene ID
607
UniProt ID
O00512
Alternative Names
B Cell CLL/Lymphoma 9; B-Cell Lymphoma 9 Protein; Protein Legless Homolog; Bcl-9; B-Cell CLL/Lymphoma 9 Protein; B-Cell CLL/Lymphoma 9; LGS;
Function
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity (By similarity).
Biological Process
Beta-catenin-TCF complex assembly Source: Reactome
Canonical Wnt signaling pathway Source: GO_Central
Myotube differentiation involved in skeletal muscle regeneration Source: Ensembl
Positive regulation of transcription by RNA polymerase II Source: GO_Central
Skeletal muscle cell differentiation Source: Ensembl
Somatic stem cell population maintenance Source: Ensembl
Cellular Location
Nucleus
Involvement in disease
A chromosomal aberration involving BCL9 is found in a patient with precursor B-cell acute lymphoblastic leukemia (ALL). Translocation t(1;14)(q21;q32). This translocation leaves the coding region intact, but may have pathogenic effects due to alterations in the expression level of BCL9. Several cases of translocations within the 3'-UTR of BCL9 have been found in B-cell malignancies.

Zhuang, W., Mei, F., Wu, C., Shen, S., & Zhu, D. (2020). Bcl9 depletion modulates endothelial cell in tumor immune microenvironment in colorectal cancer tumor. Frontiers in oncology, 10, 2900.

Huge, N., Sandbothe, M., Schröder, A. K., Stalke, A., Eilers, M., Schäffer, V., ... & Skawran, B. (2020). Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma. Hepatology international, 14(3), 373-384.

Wang, J., Zheng, M., Zhu, L., Deng, L., Li, X., Gao, L., ... & Lin, B. (2019). Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells. Cancer cell international, 19(1), 1-16.

Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., ... & Zhu, D. (2019). Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Science advances, 5(5), eaau5240.

Yang, G., Zhang, J., You, W., Zhao, X., Hou, P., He, W., ... & Guo, H. (2019). Targeted disruption of the BCL9/β-catenin interaction by endosomal-escapable nanoparticles functionalized with an E-cadherin-derived peptide. Nanotechnology, 31(11), 115102.

Fan, R., He, H., Yao, W., Zhu, Y., Zhou, X., Gui, M., ... & Fan, M. (2018). SOX7 suppresses Wnt signaling by disrupting β-Catenin/BCL9 interaction. DNA and cell biology, 37(2), 126-132.

Sun, Z., Jian, Y., Fu, H., & Li, B. (2018). MiR-532 downregulation of the Wnt/β-catenin signaling via targeting Bcl-9 and induced human intervertebral disc nucleus pulposus cells apoptosis. Journal of pharmacological sciences, 138(4), 263-270.

Yang, C., Xu, Y., Cheng, F., Hu, Y., Yang, S., Rao, J., & Wang, X. (2017). miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9. Cell death & disease, 8(8), e2999-e2999.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-BCL9 Recombinant Antibody (CBYY-1990)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare